Project Grant K99CA293261
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $112K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- The National Cancer Institute awarded a Cooperative Agreement of $767,324 on April 1, 2025 to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan under the Cancer Biology Research program (CFDA 93.396). The funding will support research to investigate how dietary caloric restriction can boost anti-tumor immunity by impacting the metabolism and function of CD8 T cells in the tumor microenvironment. The research aims to identify novel diet-regulated mechanisms linking nutrient...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The National Institutes of Health (NIH) National Cancer Institute awarded a $618,928 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Berkeley. The 5-year grant, awarded on June 9, 2025, will fund research to investigate the mechanisms by which regulatory T cells (Tregs) within tumors suppress antitumor immune responses. The project aims to determine if blocking Treg function solely within the tumor microenvironment is sufficient to control...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- This $149,804 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the University of Pittsburgh to investigate the impact of the LAG3 receptor on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research aims to elucidate how LAG3 functions to restrict T cell motility, and determine if LAG3 affects CD8+ T cell infiltration and interactions within the tumor microenvironment. The research combines...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), provides $121,857 to the University of Pittsburgh to systematically investigate the impact of anti-cancer drugs on T cells within the tumor microenvironment. The award aims to identify novel drug combinations that can overcome resistance to immune checkpoint blockade therapies in cancer treatment. Specifically, the research will involve in silico screening of anti-cancer drugs for their...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- The National Cancer Institute (NCI) awarded a $169,776 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The project, titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution," aims to investigate the role of specific myeloid cell subsets in mediating resistance to immune checkpoint inhibitors in metastatic castration-resistant...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,340.00 to the Regents of the University of Michigan to conduct research focused on understanding the role of the MS4A14 protein in regulating macrophage activation and its impact on anti-tumor immunity. The award period runs from Dec 12, 2025 to Jun 16, 2028. The research aims to investigate how MS4A14 expression in macrophages influences their ability to present antigens and...